Trials@Home Annual Meeting – 26 & 27 September 2022

Wuppertal & Online

The 2022 Trials@Home Annual Meeting took place in Bayer’s facilities in Wuppertal, where we had two full days of meetings, presentations, and networking. The project thanks Bayer for allowing use of their space for this meeting and for their support in the meeting organisation. The project also thanks the members from the Scientific Advisory Board (SAB), External Stakeholder Platform (ESP) and Patient Expert Panel (PEP) for their invaluable contributions so far.

With about 60 people in the room and 40 online attendees, we had a great time with a lot of inspiring and thought-provoking sessions. Some highlights are presented below.

Overall Progress

An important part of the meeting was the presentation on Work Package progress. The draft recommendations with best practices for Decentralised Clinical Trials (DCTs) are still standing today but WP BEST is working on updating this through follow-up interviews and new case studies. WP TECH and WP PILOT and WP EAGLE are working hard on preparations for RADIAL, the Trials@Home proof-of-concept study. RADIAL updates will be discussed in more detail in the next section. Besides this, WP PILOT is executing a Patient Preference Study for which they are currently setting up focus groups in various EU countries, as well as a Digital Literacy study and a Physical Examination project. WP EAGLE is focusing on the regulatory and ethical aspects of DCTs. WP CODE is continuing their work on communication and dissemination and hosted a session at this meeting on the importance and practicalities around the project’s communication. WP PROMS is responsible for project management and is also working on the sustainability plan for Trials@Home.

Trials@Home was the main topic in more than 25 presentations during the past year, with five new published manuscripts. The manuscripts can be accessed via And you can find the posters here:

Please click here to download a copy of the full report


This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 831458. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

Notes for editors – not for publication
If you would like more information, please contact the spokesperson at the UMC Utrecht.
Joris Prinssen: +31 6 2571 0234